Drug
HLX13 clinical trials
Also written HLX13.
Keep track of what changes. Save the HLX13 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses HLX13 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingPhase 1Shanghai Henlius BiotechNCT07176650Written as HLX13
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 3Shanghai Henlius BiotechNCT06841185Written as HLX13
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsRecruitingPhase 1Shanghai Henlius BiotechNCT06159101Written as HLX13